샘플 요청 목록

 카트 문의
시장보고서
상품코드
2154131

감염증 진단 시장

Infectious Disease Diagnostics
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 756 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,891,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 14,993,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,673,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 감염증 진단약 시장은 2032년까지 475억 달러에 달할 전망

2025년에 258억 달러로 추정되는 세계의 감염증 진단 시장은 2032년까지 475억 달러에 달할 것으로 예상되고 있으며, 2025-2032년까지의 분석 기간에 CAGR 9.1%로 성장할 것으로 전망되고 있습니다. 이 리포트에서 분석 대상이 되고 있는 부문의 하나인 시약/키트/소모품 분야는 9.1%의 CAGR을 기록하며, 분석 기간의 종료까지 201억 달러에 달할 것으로 예상되고 있습니다. 기기 분야의 성장률은 분석 기간 중 10.8%의 CAGR에 달할 것으로 추정되고 있습니다.

미국 시장은 70억 달러로 추계되는 한편, 중국은 CAGR 13.8%로 성장할 것으로 예측됩니다.

미국의 감염증 진단 시장은 2025년에 70억 달러로 추계되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025-2032년의 분석 기간에 CAGR 13.8%로 추이하며, 2032년까지 시장 규모가 107억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 CAGR 4.9% 및 8.6%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 6.3%로 성장할 것으로 예측됩니다.

감염증 진단 시장 - 주요 동향과 촉진요인 정리

감염병 진단이란 무엇이며, 왜 공중보건에 필수적인 것인가?

감염병 진단이란, 인체 검체 내에 존재하는 세균, 바이러스, 진균, 기생충 등의 병원체 유무를 확인하기 위해 사용되는 검사나 절차를 말합니다. 이러한 진단법은 감염병의 조기 발견, 진단, 관리를 가능하게 하여 감염 확산을 방지하고 발병률 및 사망률을 낮추기 때문에 공중보건에 있으며, 매우 중요합니다. 사용되는 기술에는 기존의 배양법, 혈청학적 검사, 그리고 중합효소 연쇄반응(PCR) 및 차세대 염기서열 분석(NGS)과 같은 첨단 분자생물학적 기법이 포함됩니다. 이러한 툴들은 사례의 신속한 확인과 격리가 극히 중요한 COVID-19 팬데믹과 같은 집단 감염 발생시 필수적입니다. 진단 기술의 유효성은 생의학의 발전에 따라 지속적으로 향상되고 있으며, 더 정확하고 신속하며 비용 효율적인 검사의 실현에 기여하고 있습니다.

기술의 발전은 감염병 진단의 방식을 어떻게 변화시키고 있는가?

감염병 진단의 방식은 놀라운 기술적 진보에 의해 재편되고 있습니다. POC(Point-Of-Care) 검사 장비와 같은 혁신 기술 덕분에 전문 검사 시설 없이도 현장에서 신속한 진단이 가능해졌으며, 외딴 지역이나 자원이 제한된 환경에서도 질병 진단이 용이해졌습니다. 또한 감염병 발생을 실시간으로 추적하는 건강 정보 시스템을 포함한 디지털 헬스 기술의 통합으로 질병 감시 및 대응의 효율이 향상되고 있습니다. 분자 진단 기술, 특히 PCR 및 CRISPR에 기반한 진단법은 병원체 검출에 있으며, 높은 민감도와 특이성을 제공함으로써 이 분야에 혁명을 가져왔습니다. 이러한 진보는 진단 능력을 향상시킬 뿐만 아니라, 진단 결과를 바탕으로 개별 환자의 필요에 맞춘 치료 개입을 수행하는 맞춤형 치료 접근법을 촉진하고 있습니다.

감염병 진단 시장에 영향을 미치고 있는 글로벌 동향은 무엇인가?

감염병 진단 시장에 영향을 미치는 세계적 동향은 여러 가지가 있지만, 특히 감염병 발생률의 증가와 결핵, 말라리아 등의 질병 재유행을 들 수 있습니다. 도시화와 국제적 이동은 감염병의 급속한 확산에 기여하고 있으며, 효과적인 진단 툴의 필요성을 부각시키고 있습니다. 기후 변화도 한 요인으로 작용하고 있으며, 기온 및 강수 패턴의 변화가 매개체 매개 질환의 분포에 영향을 미쳐 진단법에 대한 수요를 높이고 있습니다. 또한 항생제 내성의 증가로 인해 내성 병원체를 신속하게 식별하고 적절한 치료 방침을 결정할 수 있는 진단법의 개발이 시급합니다. 이러한 동향으로 인해 풍토병과 신종 감염병을 모두 관리하기 위해 전 세계에서 적용 가능한 견고하고 확장성이 뛰어난 진단 솔루션이 요구되고 있습니다.

감염병 진단 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

감염병 진단 시장의 성장은 기술 혁신, 역학적 변화, 의료 인프라 발전 등 여러 요인에 의해 주도되고 있습니다. 더 신속하고, 더 정확하며 비용 효율적인 진단 검사를 실현하는 기술의 진보는 감염병 집단 발생이나 풍토병을 효과적으로 관리하는 능력을 향상시키기 위해 매우 중요합니다. 국제 여행의 증가나 도시화와 같은 요인으로 인해 전 세계에서 증가하고 있는 감염병의 부담 또한 첨단 진단법에 대한 수요를 촉진하는 데 중요한 역할을 하고 있습니다. 또한 예방 의료 및 조기 진단에 초점을 맞춘 정부 및 의료 정책 역시 시장 확대에 큰 영향을 미치고 있습니다. 특히 개발도상 지역의 의료 인프라에 대한 투자를 통해 진단 서비스에 대한 접근성이 확대되면서 시장 성장을 더욱 촉진하고 있습니다. 소비자 행동, 특히 COVID-19 팬데믹 이후 높아진 건강 의식과 예방 조치에 대한 관심은 일상적인 의료 현장에서 이러한 진단법의 도입을 지속적으로 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용하여 감염병 진단 시장의 역동적인 확장을 지원하고 있으며, 이는 전 세계에서 보다 적극적이고 예방적인 의료 전략으로의 전환을 반영하고 있습니다.

부문:

구성 요소(시약/키트/소모품, 기기, 소프트웨어 및 서비스), 검사( 임상 검사, POC 검사), 검체(혈액/혈청/혈장, 뇨, 기타 검체), 질환(간염, HIV 감염증, 원내감염, 모기 매개성 질환, HPV 감염증, 클라미디아·트라코마티스 감염증, 임균 감염증, 결핵, 기타 질환), 최종사용자(진단 검사 실, 병원·진료소, 학술연구기관, 기타 최종사용자)

주요 기업

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Meridian Bioscience, Inc.
  • Quidel Corporation
  • Siemens AG
  • Thermo Fisher Scientific, Inc.

해당 분야의 전문가 관점을 바탕으로 합니다.. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다. - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업의 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있으며, 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다. - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 관여하고 있는 기업을 상세히 검증합니다.

주요 지역의 시장 점유율을 면밀히 검토합니다. - 단일 글로벌 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구조는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞춰 상세도를 조정하여 주요 지역의 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 26.10.27

Global Infectious Disease Diagnostics Market to Reach US$47.5 Billion by 2032

The global market for Infectious Disease Diagnostics estimated at US$25.8 Billion in the year 2025, is expected to reach US$47.5 Billion by 2032, growing at a CAGR of 9.1% over the analysis period 2025-2032. Reagents / Kits / Consumables Component, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$20.1 Billion by the end of the analysis period. Growth in the Instruments Component segment is estimated at 10.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.0 Billion While China is Forecast to Grow at 13.8% CAGR

The Infectious Disease Diagnostics market in the U.S. is estimated at US$7.0 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$10.7 Billion by the year 2032 trailing a CAGR of 13.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Infectious Disease Diagnostics Market - Key Trends & Drivers Summarized

What Are Infectious Disease Diagnostics and Why Are They Fundamental to Public Health?

Infectious disease diagnostics comprise tests and procedures used to identify the presence of pathogens like bacteria, viruses, fungi, or parasites in human samples. These diagnostics are fundamental to public health as they enable early detection, diagnosis, and management of infections, thereby preventing their spread and reducing morbidity and mortality. Technologies utilized include traditional culture techniques, serological assays, and advanced molecular methods like polymerase chain reaction (PCR) and next-generation sequencing. These tools are vital in outbreak situations, such as the COVID-19 pandemic, where rapid identification and isolation of cases are critical. The effectiveness of diagnostics is continually enhanced by advancements in biomedical science, contributing to more accurate, faster, and cost-effective tests.

How Is Technological Advancement Shaping the Landscape of Infectious Disease Diagnostics?

The landscape of infectious disease diagnostics is being reshaped by significant technological advancements. Innovations such as point-of-care (POC) testing devices allow for rapid, on-site diagnosis without the need for specialized laboratory facilities, making it easier to diagnose diseases in remote or resource-limited settings. Additionally, the integration of digital health technologies, including health information systems that track disease outbreaks in real time, is improving the efficiency of disease surveillance and response. Molecular diagnostic techniques, particularly PCR and CRISPR-based diagnostics, have revolutionized the field by providing high sensitivity and specificity in detecting pathogens. These advancements not only enhance diagnostic capabilities but also facilitate personalized treatment approaches, tailoring interventions to individual patient needs based on diagnostic results.

What Global Trends Are Influencing the Infectious Disease Diagnostics Market?

Several global trends are influencing the infectious disease diagnostics market, notably the increasing incidence of infectious diseases and the resurgence of conditions such as tuberculosis and malaria. Urbanization and global travel contribute to the rapid spread of infections, highlighting the need for effective diagnostic tools. Climate change also plays a role, as changing temperatures and precipitation patterns affect the distribution of vector-borne diseases, increasing the demand for diagnostics. Furthermore, the rise in antimicrobial resistance is prompting the development of diagnostics that can quickly identify resistant pathogens and guide appropriate treatment decisions. These trends necessitate robust, scalable diagnostic solutions that can be deployed globally to manage both endemic diseases and emerging infections.

Growth in the Infectious Disease Diagnostics Market Is Driven by Several Factors

The growth in the infectious disease diagnostics market is driven by several factors, including technological innovations, epidemiological shifts, and healthcare infrastructure developments. Technological advances that offer quicker, more accurate, and cost-effective diagnostic tests are crucial, as they improve the capacity to manage outbreaks and endemic diseases effectively. The increasing global burden of infectious diseases, driven by factors such as increased international travel and urbanization, also plays a significant role in fueling the demand for advanced diagnostics. Additionally, government and healthcare policies focusing on preventive care and early diagnosis are significantly influencing market expansion. Investments in healthcare infrastructure, particularly in developing regions, are enabling wider access to diagnostic services, further propelling market growth. Consumer behavior, especially heightened awareness regarding health and preventive measures following the COVID-19 pandemic, continues to drive the adoption of these diagnostics in routine healthcare practices. These combined factors underscore the dynamic expansion of the infectious disease diagnostics market, reflecting a global shift towards more proactive and preventive healthcare strategies.

SCOPE OF STUDY:

The report analyzes the Infectious Disease Diagnostics market by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Reagents / Kits / Consumables Component, Instruments Component, Software & Services Component); Testing (Laboratory Testing, POC Testing); Sample (Blood / Serum / Plasma Sample, Urine Sample, Other Samples); Disease (Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease, Other Diseases); End-Use (Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Meridian Bioscience, Inc.
  • Quidel Corporation
  • Siemens AG
  • Thermo Fisher Scientific, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Infectious Disease Diagnostics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 213 Players Worldwide in 2026 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Infectious Diseases Spurs Demand for Advanced Diagnostic Solutions
    • Advancements in Molecular Diagnostics Propel Growth in Infectious Disease Testing
    • COVID-19 Pandemic Throws the Spotlight on Importance of Rapid and Point-of-Care Diagnostics
    • Increasing Focus on Early Detection and Prevention Expands Addressable Market for Infectious Disease Diagnostics
    • Growing Need for Accurate and Rapid Diagnostic Results Strengthens Business Case for Innovative Technologies
    • Emergence of Multiplex Diagnostic Platforms Generates Opportunities for Comprehensive Disease Screening
    • The Role of Artificial Intelligence and Machine Learning in Enhancing Diagnostic Accuracy Sustains Market Growth
    • Rising Investment in Healthcare Infrastructure in Emerging Markets Propels Demand for Infectious Disease Diagnostics
    • Increasing Consumer Awareness and Access to Testing Drives Adoption of At-Home Diagnostic Kits
    • Growing Emphasis on Personalized Medicine and Targeted Therapies Expands Use of Precision Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Infectious Disease Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Reagents / Kits / Consumables Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Reagents / Kits / Consumables Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Reagents / Kits / Consumables Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Instruments Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Instruments Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Software & Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Software & Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Software & Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Laboratory Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for POC Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for POC Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for POC Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Blood / Serum / Plasma Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Blood / Serum / Plasma Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Blood / Serum / Plasma Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Other Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Other Samples by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Hepatitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Hepatitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Hepatitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for HIV Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for HIV Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for HIV Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital-acquired Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Hospital-acquired Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Hospital-acquired Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Mosquito-borne Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Mosquito-borne Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Mosquito-borne Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for HPV Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for HPV Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for HPV Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Chlamydia Trachomatis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Chlamydia Trachomatis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Chlamydia Trachomatis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 47: World Recent Past, Current & Future Analysis for Neisseria Gonorrhea Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 48: World Historic Review for Neisseria Gonorrhea Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: World 13-Year Perspective for Neisseria Gonorrhea Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 50: World Recent Past, Current & Future Analysis for Tuberculosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 51: World Historic Review for Tuberculosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: World 13-Year Perspective for Tuberculosis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 53: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 54: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: World 13-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 56: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 57: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: World 13-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 59: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 60: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: World 13-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 62: World Recent Past, Current & Future Analysis for Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 63: World Historic Review for Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: World 13-Year Perspective for Academic Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 65: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 66: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 68: USA Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: USA Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: USA 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 71: USA Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: USA Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: USA 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 74: USA Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: USA Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: USA 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 77: USA Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: USA Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: USA 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 80: USA Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: USA Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: USA 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Canada Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Canada 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Canada Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Canada 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 89: Canada Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Canada Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Canada 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 92: Canada Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Canada Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Canada 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 95: Canada Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Canada Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Canada 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • JAPAN
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Japan Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Japan 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 101: Japan Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Japan Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Japan 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 104: Japan Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Japan Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Japan 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 107: Japan Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Japan Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Japan 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 110: Japan Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Japan Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Japan 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CHINA
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 113: China Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: China Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: China 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 116: China Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: China Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: China 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 119: China Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: China Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: China 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 122: China Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: China Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: China 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 125: China Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: China Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: China 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • EUROPE
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 129: Europe Historic Review for Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Europe 13-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 131: Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Europe Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Europe 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 134: Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Europe Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Europe 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 137: Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Europe Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Europe 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 140: Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Europe Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Europe 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 143: Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Europe Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Europe 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • FRANCE
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 146: France Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: France Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: France 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 149: France Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: France Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: France 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 152: France Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: France Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: France 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 155: France Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: France Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: France 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 158: France Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: France Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: France 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • GERMANY
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 161: Germany Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Germany Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Germany 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 164: Germany Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Germany Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Germany 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 167: Germany Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Germany Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Germany 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 170: Germany Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Germany Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Germany 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 173: Germany Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Germany Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Germany 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 176: Italy Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Italy Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Italy 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 179: Italy Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Italy Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Italy 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 182: Italy Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Italy Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Italy 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 185: Italy Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Italy Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Italy 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 188: Italy Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Italy Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Italy 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 191: UK Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: UK Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: UK 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 194: UK Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: UK Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: UK 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 197: UK Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: UK Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: UK 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 200: UK Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: UK Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: UK 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 203: UK Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: UK Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: UK 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 206: Spain Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Spain Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Spain 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 209: Spain Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Spain Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Spain 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 212: Spain Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Spain Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Spain 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 215: Spain Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Spain Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Spain 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 218: Spain Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Spain Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Spain 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 221: Russia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Russia Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Russia 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 224: Russia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Russia Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Russia 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 227: Russia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Russia Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Russia 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 230: Russia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Russia Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Russia 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 233: Russia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Russia Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Russia 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Europe Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Europe 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Europe Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Europe 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Europe Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Europe 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 245: Rest of Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Europe Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Europe 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 248: Rest of Europe Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Europe Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Europe 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 263: Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 266: Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Asia-Pacific Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 269: Australia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Australia Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Australia 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 272: Australia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Australia Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Australia 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 275: Australia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Australia Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Australia 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 278: Australia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Australia Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Australia 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 281: Australia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Australia Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Australia 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • INDIA
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 284: India Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: India Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: India 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 287: India Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: India Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: India 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 290: India Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: India Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: India 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 293: India Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: India Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: India 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 296: India Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: India Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: India 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 299: South Korea Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: South Korea Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: South Korea 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 302: South Korea Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: South Korea Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: South Korea 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 305: South Korea Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: South Korea Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: South Korea 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 308: South Korea Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: South Korea Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: South Korea 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 311: South Korea Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: South Korea Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: South Korea 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Rest of Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 323: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Rest of Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 326: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Rest of Asia-Pacific 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 330: Latin America Historic Review for Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 331: Latin America 13-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 332: Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Latin America Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 334: Latin America 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 335: Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Latin America Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 337: Latin America 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 338: Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Latin America Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 340: Latin America 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 341: Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Latin America Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 343: Latin America 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 344: Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Latin America Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 346: Latin America 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 347: Argentina Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Argentina Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 349: Argentina 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 350: Argentina Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Argentina Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 352: Argentina 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 353: Argentina Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Argentina Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 355: Argentina 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 356: Argentina Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Argentina Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 358: Argentina 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 359: Argentina Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Argentina Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 361: Argentina 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 362: Brazil Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Brazil Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 364: Brazil 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 365: Brazil Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Brazil Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 367: Brazil 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 368: Brazil Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 369: Brazil Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 370: Brazil 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 371: Brazil Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 372: Brazil Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 373: Brazil 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 374: Brazil Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 375: Brazil Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 376: Brazil 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 377: Mexico Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 378: Mexico Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 379: Mexico 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 380: Mexico Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 381: Mexico Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 382: Mexico 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 383: Mexico Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 384: Mexico Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 385: Mexico 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 386: Mexico Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 387: Mexico Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 388: Mexico 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 389: Mexico Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Mexico Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 391: Mexico 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 394: Rest of Latin America 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 397: Rest of Latin America 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 400: Rest of Latin America 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 401: Rest of Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 402: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 403: Rest of Latin America 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 404: Rest of Latin America Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 405: Rest of Latin America Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 406: Rest of Latin America 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 408: Middle East Historic Review for Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 409: Middle East 13-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 410: Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 411: Middle East Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 412: Middle East 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 413: Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 414: Middle East Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 415: Middle East 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 416: Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 417: Middle East Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 418: Middle East 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 419: Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 420: Middle East Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 421: Middle East 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 422: Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 423: Middle East Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 424: Middle East 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 425: Iran Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 426: Iran Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 427: Iran 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 428: Iran Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 429: Iran Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 430: Iran 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 431: Iran Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 432: Iran Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 433: Iran 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 434: Iran Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 435: Iran Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 436: Iran 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 437: Iran Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 438: Iran Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 439: Iran 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 440: Israel Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 441: Israel Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 442: Israel 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 443: Israel Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 444: Israel Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 445: Israel 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 446: Israel Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 447: Israel Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 448: Israel 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 449: Israel Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 450: Israel Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 451: Israel 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 452: Israel Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 453: Israel Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 454: Israel 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 456: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 457: Saudi Arabia 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 459: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 460: Saudi Arabia 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 462: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 463: Saudi Arabia 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 464: Saudi Arabia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 465: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 466: Saudi Arabia 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 467: Saudi Arabia Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 468: Saudi Arabia Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 469: Saudi Arabia 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 470: UAE Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 471: UAE Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 472: UAE 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 473: UAE Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 474: UAE Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 475: UAE 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 476: UAE Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 477: UAE Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 478: UAE 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 479: UAE Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 480: UAE Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 481: UAE 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 482: UAE Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 483: UAE Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 484: UAE 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 486: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 487: Rest of Middle East 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 489: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 490: Rest of Middle East 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 492: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 493: Rest of Middle East 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 494: Rest of Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 495: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 496: Rest of Middle East 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 497: Rest of Middle East Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 498: Rest of Middle East Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 499: Rest of Middle East 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AFRICA
    • Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 500: Africa Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 501: Africa Historic Review for Infectious Disease Diagnostics by Component - Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 502: Africa 13-Year Perspective for Infectious Disease Diagnostics by Component - Percentage Breakdown of Value Sales for Reagents / Kits / Consumables Component, Instruments Component and Software & Services Component for the Years 2020, 2026 & 2032
    • TABLE 503: Africa Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 504: Africa Historic Review for Infectious Disease Diagnostics by Testing - Laboratory Testing and POC Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 505: Africa 13-Year Perspective for Infectious Disease Diagnostics by Testing - Percentage Breakdown of Value Sales for Laboratory Testing and POC Testing for the Years 2020, 2026 & 2032
    • TABLE 506: Africa Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 507: Africa Historic Review for Infectious Disease Diagnostics by Sample - Blood / Serum / Plasma Sample, Urine Sample and Other Samples Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 508: Africa 13-Year Perspective for Infectious Disease Diagnostics by Sample - Percentage Breakdown of Value Sales for Blood / Serum / Plasma Sample, Urine Sample and Other Samples for the Years 2020, 2026 & 2032
    • TABLE 509: Africa Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 510: Africa Historic Review for Infectious Disease Diagnostics by Disease - Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 511: Africa 13-Year Perspective for Infectious Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for Hepatitis Disease, HIV Disease, Hospital-acquired Disease, Mosquito-borne Disease, HPV Disease, Chlamydia Trachomatis Disease, Neisseria Gonorrhea Disease, Tuberculosis Disease and Other Diseases for the Years 2020, 2026 & 2032
    • TABLE 512: Africa Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 513: Africa Historic Review for Infectious Disease Diagnostics by End-Use - Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 514: Africa 13-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals & Clinics End-Use, Academic Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기